

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION 10

About the Fifth Edition **10**

About Tuberculosis **12**

Innovations in Tuberculosis Care in the Last Decade **13**

The Role of the Bureau of Tuberculosis Control in Tuberculosis Care and Prevention in New York City **15**

CHAPTER 2: DIAGNOSIS AND TREATMENT OF LATENT TUBERCULOSIS INFECTION 18

Priority Populations for Tuberculosis Infection Screening and Evaluation **19**

Tests for Tuberculosis Infection **19**

Testing Among Priority Populations and Special Considerations **28**

Medical Evaluation **31**

Classification of the Patient and Implications for Clinical Follow-Up **32**

Treatment Of Latent Tuberculosis Infection **35**

Clinical Monitoring During Latent Tuberculosis Infection Treatment **43**

Special Considerations For Latent Tuberculosis Infection Diagnosis And Treatment During Pregnancy **46**

Special Considerations for Diagnosis and Treatment of Latent Tuberculosis Infection in Infant and Child Contacts **49**

Special Considerations for Contacts of Persons with Multidrug-Resistant Tuberculosis **51**

Special Considerations for Treatment Options of Persons with Radiographic Evidence of Old, Healed Tuberculosis **52**

Case Management of Patients with Latent Tuberculosis Infection **54**

Discharge of the Patient from Clinic **55**

Re-Treatment of Latent Tuberculosis Infection **55**

CHAPTER 3: DIAGNOSIS OF TUBERCULOSIS DISEASE IN ADULTS 62

Diagnosis of Active Tuberculosis Disease **63**

Evaluation of Extrapulmonary Tuberculosis Disease **71**

CHAPTER 4: LABORATORY TESTING FOR TUBERCULOSIS 79

General Information About Laboratory Tests for New York City Specimens **79**

Tests for Tuberculosis Disease **82**

Testing for Drug Susceptibility and Prediction of Drug Resistance **85**

Genotyping **91**

False-Positive Investigation **92**

Other Laboratory Testing **93**

CHAPTER 5: TREATMENT OF DRUG-SUSCEPTIBLE TUBERCULOSIS DISEASE IN ADULTS 96

Treatment Regimens and Dosages for Pulmonary Tuberculosis Disease **97**

Treatment of Extrapulmonary Tuberculosis Disease **101**

Use of Pyridoxine (Vitamin B6) in Tuberculosis Treatment **103**

Determination of Treatment Completion **103**

TABLE OF CONTENTS

- Treatment of Coexisting Tuberculosis Disease and Human Immunodeficiency Virus **106**
- Treatment of Coexisting Tuberculosis and Nontuberculous Mycobacteria **111**
- Treatment Regimens for Pregnant Patients **111**
- Treatment Regimens for Patients with Chronic Renal Failure **112**
- Treatment Regimens for Patients with Liver Disease **113**
- Drug Interactions **114**

CHAPTER 6: TREATMENT OF DRUG-RESISTANT TUBERCULOSIS DISEASE IN ADULTS 117

- Principles of Treating Drug-Resistant Tuberculosis Disease **118**
- Specific Medications Used to Treat Drug-Resistant Tuberculosis **121**
- Suggested Regimens for Specific Drug Resistance Patterns **127**
- Treatment Regimens for Multidrug-Resistant Tuberculosis **131**
- Principles of Monitoring Drug-Resistant Tuberculosis Disease **134**
- QTc Prolongation **134**
- Surgery for Pulmonary Tuberculosis Disease **135**
- Shorter Regimens for Multidrug-Resistant Tuberculosis **136**
- Post-Treatment Evaluation **137**

CHAPTER 7: DIAGNOSIS AND TREATMENT OF PEDIATRIC TUBERCULOSIS DISEASE 141

- Characteristics of Pediatric Tuberculosis Disease **142**
- Medical Evaluation **142**
- Lumbar Puncture **145**
- Congenital and Neonatal Tuberculosis Disease **146**
- Treatment of Pediatric Tuberculosis Disease **148**
- Adverse Events in Children **152**

CHAPTER 8: CLINICAL MONITORING AND FOLLOW-UP FOR TUBERCULOSIS TREATMENT 154

- Monthly Clinical Monitoring **155**
- Management of Adverse Reactions **160**
- Drug Desensitization **172**
- Paradoxical Reactions/Immune Reconstitution Inflammatory Syndrome **172**
- Reporting Adverse Events **173**
- Re-Classification of Patients Being Evaluated for Tuberculosis Disease **174**
- Monitoring Serum Drug Levels **175**
- Late Complications of Treated Pulmonary Tuberculosis Disease **176**

CHAPTER 9: TUBERCULOSIS REPORTING AND SURVEILLANCE 180

- Tuberculosis Reporting **181**
- Surveillance **184**

TABLE OF CONTENTS

CHAPTER 10: CASE MANAGEMENT FOR PATIENTS WITH TUBERCULOSIS 188

- Case Management Activities **189**
- Directly Observed Therapy **194**
- Addressing Non-Adherence **195**
- Ensuring Effective Case Management **201**

CHAPTER 11: CONTACT INVESTIGATION 206

- Contact Investigation Activities **206**
- Source Case Investigations **221**
- Addressing Non-Adherence **222**

CHAPTER 12: TUBERCULOSIS GENOTYPING AND CLUSTER INVESTIGATION 224

- Tuberculosis Genotyping **224**
- Tuberculosis Genotype Review And Cluster Detection **225**
- Cluster Prioritization **226**
- Cluster Investigation **227**
- Tuberculosis Outbreaks **230**
- Initiating Public Health Action **230**

CHAPTER 13: INFECTION CONTROL 233

- General Principles of Infection Control **233**
- Hierarchy of Infection Control Measures **234**
- Tuberculosis Infection Control in Healthcare Facilities **238**
- Infection Control Measures in the Community **241**
- Discontinuation of Infection Control Measures **243**
- Regulatory Controls for Infectious Non-Adherent Patients **245**
- Special Considerations for Pregnancy and Peripartum Infection Control **245**
- Bureau of Tuberculosis Control Infection Control Plan **246**

CHAPTER 14: OUTREACH AND EDUCATION 249

- Planning Framework for Education, Training, and Outreach **253**

CHAPTER 15: TUBERCULOSIS EVALUATION FOR NEW ARRIVALS AND STATUS ADJUSTERS 258

- New Arrival Medical Screening for Tuberculosis **259**
- Bureau of Tuberculosis Control New Arrival Activities **261**
- Status Adjuster Medical Screening for Tuberculosis **263**

CHAPTER 16: PROGRAM EVALUATION AND RESEARCH 267

- Data Sources and Routine Analysis **267**
- Program Evaluation **268**
- Research **271**

TABLE OF CONTENTS

CHAPTER 17: LAWS GOVERNING TUBERCULOSIS IN NEW YORK CITY 274

- Confidentiality and Disclosure of Patient Information **275**
- Reporting Requirements **281**
- Microbiology and Pathology Laboratories: Testing and Reporting **285**
- Veterinarian and Animal Care Institutions: Reporting Animals Infected with Tuberculosis **287**
- Investigation, Isolation, Exclusion Requirements, and Enforcement Mechanisms for Non-Adherent Patients **289**
- Schools, Childcare Services, and Other Children’s Facilities **293**
- Payment for Tuberculosis Services **295**

APPENDICES 297

- Appendix A: International Classification of Tuberculosis **298**
- Appendix B: Tuberculosis Risk Assessment Tool **299**
- Appendix C: Administering the Tuberculin Skin Test **300**
- Appendix D: The Use of Bacille Calmette-Guérin Vaccine **302**
- Appendix E: Instructions for Performing Sputum Induction **304**
- Appendix F: Potential Drug Interactions with Isoniazid and Rifamycin Medications **308**
- Appendix G: Dosages, Adverse Reactions, and Monitoring for First-Line Medications Used to Treat Tuberculosis **310**
- Appendix H: Dosages, Adverse Reactions, and Monitoring for Additional Medications Used to Treat Tuberculosis **312**
- Appendix I: The Use of Anti-Tuberculosis Drugs and Pregnancy, Breastfeeding, Tuberculosis Meningitis, and Renal and Hepatic Failure¹ **315**
- Appendix J: Recommendations for Patients to Assist with Taking Tuberculosis Medications **317**
- Appendix K: Procedures for Therapeutic Drug Monitoring **318**
- Appendix L: Initial Patient Interview Topics **321**
- Appendix M: Directly Observed Therapy Agreement Form **322**
- Appendix N: Home Isolation Agreement **324**
- Appendix O: Instructions for Patients with Potentially Infectious TB **325**
- Appendix P: Information for Persons who Live with Patients with TB **326**
- Appendix Q: New York City Health Department Universal Reporting Form **327**
- Appendix R: Report of Patient Services Form **331**
- Appendix S: Hospital Discharge Approval Form **332**